---
title: "Hong Kong Biotech Stocks Decline as BeiGene and WuXi Biologics Lead Losses"
description: "Hong Kong's biotech sector experienced a downturn with significant declines in key stocks. According to Jin10, BeiGenesaw a drop of over 9%, while WuXi Biologicsfell more than 7%. Other companies, inc"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277000272.md"
published_at: "2026-02-26T07:34:07.000Z"
---

# Hong Kong Biotech Stocks Decline as BeiGene and WuXi Biologics Lead Losses

> Hong Kong's biotech sector experienced a downturn with significant declines in key stocks. According to Jin10, BeiGenesaw a drop of over 9%, while WuXi Biologicsfell more than 7%. Other companies, including WuXi AppTecand Junshi Biosciences, also followed the downward trend. The sector's performance reflects broader market challenges impacting the innovative drug segment.

Hong Kong's biotech sector experienced a downturn with significant declines in key stocks. According to Jin10, BeiGene (06160.HK) saw a drop of over 9%, while WuXi Biologics (02269.HK) fell more than 7%. Other companies, including WuXi AppTec (02359.HK) and Junshi Biosciences (01877.HK), also followed the downward trend. The sector's performance reflects broader market challenges impacting the innovative drug segment.

### Related Stocks

- [159615.CN - China Southern Hang Seng Biotech ETF(QDII)](https://longbridge.com/en/quote/159615.CN.md)
- [520500.CN - Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/520500.CN.md)
- [513120.CN - GF CSI HK Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/513120.CN.md)
- [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md)
- [06160.HK - BEONE MEDICINES](https://longbridge.com/en/quote/06160.HK.md)
- [WXXWY.US - WuXi Biologics](https://longbridge.com/en/quote/WXXWY.US.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [02269.HK - WUXI BIO](https://longbridge.com/en/quote/02269.HK.md)
- [159570.CN - China Universal CNI HK Connect Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159570.CN.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Top 5 港股千亿以上公司涨跌幅（2月26日） | 东方电气 (01072) 涨 15.52%，成交额 14.1 亿港元，年内累计涨 62%。 豪威集团 (00501) 涨 6.91%，成交额 1.7 亿港元，年内累计涨 4.8%。 百济神州 (06160) 跌 9.16%，成交额 12.1 | [Link](https://longbridge.com/en/news/277006258.md) |
| 百济神州公布了 2025 年的业绩，并对 2026 年的展望持谨慎态度 | 百济神州有限公司是一家总部位于瑞士并在香港上市的生物制药公司，已发布 2025 年第四季度未经审计的合并财务结果和全年审计结果。该公司对 2026 年提供了谨慎的财务展望，强调该指导意见为初步，可能因临床和监管风险而有所变化。最新的分析师评 | [Link](https://longbridge.com/en/news/277035413.md) |
| 百济神州 Q4 营收同比增长 33%，全年扭亏为盈，百悦泽单季狂揽 11 亿创历史新高｜财报见闻 | 百济神州 2025 年全年营收 53.43 亿美元，同比增长 40%。旗舰药百悦泽全球销售额达 39 亿美元，稳居赛道第一。公司经营现金流与净利润双双转正，彻底告别 “烧钱” 模式。展望 2026 年，随新药临近商业化，总收入指引上调至 6 | [Link](https://longbridge.com/en/news/277044073.md) |
| 上海复星医药旗下子公司在中国获得肺癌药物的试验许可 | 上海复星医药子公司获得中国肺癌药物临床试验批准 | [Link](https://longbridge.com/en/news/276886600.md) |
| 上海医药获得新加坡市场批准用于抗凝药物 | 上海医药获得新加坡抗凝药物的市场批准 | [Link](https://longbridge.com/en/news/276822785.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.